Skip to main content

Table 3 Baseline Scores (Mean [standard deviation])

From: Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

 

RAM + DOC (n = 263)

PL + DOC (n = 267)

EORTC QLQ-C30 Scalesa

  

 Global QoL

62.0 (22.9)

60.8 (21.4)

 Physical functioning

75.9 (22.4)

74.2 (21.7)

 Role functioning

73.3 (29.5)

72.1 (29.9)

 Emotional functioning

76.0 (22.4)

75.0 (21.2)

 Cognitive functioning

85.9 (18.3)

84.6 (20.3)

 Social functioning

74.6 (28.8)

71.2 (30.2)

 Fatigue

33.1 (25.9)

36.0 (24.8)

 Nausea/vomiting

8.0 (16.1)

9.0 (17.5)

 Pain

32.0 (31.1)

33.8 (30.7)

 Dyspnea

17.4 (24.6)

17.9 (25.4)

 Insomnia

27.7 (30.9)

28.8 (29.9)

 Appetite loss

22.4 (29.2)

23.3 (31.9)

 Constipation

21.0 (28.3)

24.6 (30.0)

 Diarrhea

8.1 (16.6)

6.3 (16.0)

 EQ-5D-5L Index Scoreb

0.77 (0.23)

0.78 (0.19)

 EQ-5D-5L VAS

67.2 (21.7)

67.3 (18.7)

  1. DOC docetaxel, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EQ-5D-5L EuroQoL five-dimensions, n number of patients, PL placebo, QoL quality of life, RAM ramucirumab, SD standard deviation, VAS visual analogue score
  2. aFor the EORTC QLQ-C30, high scores are favorable for functional domains and global QoL; low scores are favorable for symptoms
  3. bFor the EQ-5D-5L, high scores are favorable. The range for Index Score is -0.281 to 1 and the range for VAS is 0 to 100 (higher scores are favorable)
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us